Status:

TERMINATED

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Lead Sponsor:

Aptose Biosciences Inc.

Conditions:

Acute Myelogenous Leukemia in Relapse

Acute Myelogenous Leukemia, Relapsed, Adult

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for...

Detailed Description

This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of APTO-253 in ascending cohorts (3+3 design) to determine the MTD or recommended ...

Eligibility Criteria

Inclusion

  • Patients ≥18 years old
  • Life expectancy of at least 2 months
  • Off previous cancer therapy for at least 14 days, or 5 half-lives for noncytotoxic agents prior to first study treatment administration
  • Patients must have a calculated creatinine clearance \>60 mL/min
  • Acceptable hematologic, renal and liver functions and coagulation status parameters

Exclusion

  • Patients with GVHD requiring systemic immunosuppressive therapy
  • Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder
  • Clinically significant intravascular coagulation
  • Treatment with other investigational drugs within 14 days prior to first study treatment administration

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2021

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT02267863

Start Date

October 1 2014

End Date

September 1 2021

Last Update

August 22 2022

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

University of Arizona Cancer Center

Tucson, Arizona, United States, 85724

2

UC San Diego Moores Cancer Center

La Jolla, California, United States, 92093-0698

3

University of California, Irvine

Orange, California, United States, 92868

4

Emory University; Winship Cancer Institute

Atlanta, Georgia, United States, 30322